IDENTIFICATION AND CHARACTERIZATION OF METALLO-\(\beta\)-LACTAMASES PRODUCING PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES IN AL-AZHER UNIVERSITY HOSPITAL, ASSIUT

Rehab Mousa\(^1,4\)*, Magdy F. El-Kady\(^2\), Asmaa A. A. Hussein\(^3\), Amr E. Ahmed\(^4\) and Ahmed Osama El-Gendy\(^5\)

\(^1\)Pharmacist at Al-Azher University Hospital, Assiut, Egypt
\(^2\)Department of Poultry Diseases, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef, Egypt
\(^3\)Department of Zoonoses, Faculty of Veterinary Medicine, and Dean of Molecular Biology Researches & Studies Institute, Assiut University, Assiut, Egypt
\(^4\)Department of Biotechnology and Life Sciences, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef, Egypt
\(^5\)Department of Microbiology and Immunology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt

**Purpose:** Study aimed to determine the frequency of nosocomial infections caused by *P. aeruginosa* and its distribution among different intensive care units (ICUs), to determine the antibiotic resistance pattern, and to determine the prevalence of Metallo-\(\beta\)-lactamase (M\(\beta\)L) among isolates by phenotypic methods. **Methods:** A total of 74 *P. aeruginosa* isolates were identified from different clinical specimens in AL-Azher University Hospital. The antimicrobial susceptibility was tested by disk diffusion (Kirby-Bauer) method and phenotypic screening for M\(\beta\)Ls was performed using Combined Disk Test (CDT) and double-disk synergy test (DDST). **Results:** The frequency of *P. aeruginosa* isolates from clinical specimens was 18% (74/412). The highest sensitivity was to imipenem (38 isolates (51.3%)). The antibiotic sensitivity was in descending manner to meropenem (48.6%) > levofloxacin (28.4%) > ciprofloxacin and ceftazidime (21.6%), while the highest resistance rates were to carbenicillin (94.6%) then gentamicin (70.3%). Out of 74 *P. aeruginosa* isolates, 51/74 (69%) strains were multidrug resistant (MDR), based on the CDT results 26/74 (35.1%) isolates and by DDST 23/74 (31.1%) isolates were confirmed to be M\(\beta\)Ls producers. **Conclusion:** There is a growing risk for isolation of MDR *P. aeruginosa* among the MBL-producer isolates suggests the need for continuous assessment of antimicrobial susceptibility and surveillance of antibiotic prescription. In addition, infection control measures are needed to prevent further dissemination of these organisms.

**INTRODUCTION**

Infectious diseases are one of the leading causes of death worldwide due to the development of antimicrobial resistance\(^1,2\). *P. aeruginosa* is one of the most prevalent opportunistic human pathogen causing several clinical infections including wound infection, pneumonia, urinary tract infections, endocarditis, meningitis, brain abscess, and bacteremia\(^3\). The increasing inappropriate use of broad-spectrum antibiotics has increased the emergence of multidrug resistant *P. aeruginosa* (MDRPA) isolates which complicates the
process of therapy and limits treatment options. Multidrug resistant is defined as being resistant to at least 3 anti-pseudomonal antibiotic-groups including β-lactams, aminoglycosides, and fluoroquinolones. The growing threat of antimicrobial resistance in *P. aeruginosa* relays on one hand in the extraordinary capacity of this microorganism for developing resistance to almost any available antibiotic by the selection of mutations in chromosomal genes, and on the other, in the increasing prevalence of transferable resistance determinants, particularly those encoding class B carbapenemases (or metallo-β-lactamases (MβL)). Metallo-β-lactamase (MβL) production is increasingly reported as a cause of high-level carbapenem resistance among *P. aeruginosa*, an important nosocomial pathogen that is notorious for multi-drug resistance.

**PATIENTS AND METHODS**

In this study, seventy four *P. aeruginosa* isolates were obtained from clinical specimens submitted for bacteriological testing from hospitalized in-patients admitted to AL-Azher University Hospital, and Molecular Biology Research Unit, Assiut University, Egypt during the period between November 2015 to April 2017.

**Isolation and identification of *P. aeruginosa* isolates**

These isolates were identified by standard laboratory methods including bacteriologic and biochemical methods such as: Gram staining, colony morphologies on MacConkey’s agar, biochemical tests such as oxidase, catalase, Oxidative-fermentative test, growth on media such as Triple Sugar Iron Test (TSI), cetrimide agar and growth at 42°C. These isolates were stored at -70°C in trypticase soy broth containing 20% glycerol and sub cultured twice prior to testing.

**Antimicrobial susceptibility testing**

The susceptibility pattern of isolates to different antibiotics were examined using disk diffusion method (Kirby-Bauer) on Muller-Hinton agar plates according to Clinical and Laboratory Standards Institute (CLSI). The antimicrobial disks were included: imipenem (10 μg), meropenem (10 μg), ceftazidime (30 μg), carbenicillin (100 μg), amikacin (30 μg), gentamicin (10 μg), Ciprofloxacin (5 μg), Levofloxacin (5 μg). inoculated plates and incubated overnight. The zones of inhibition were measured and interpreted.

**MIC Determination for *P. aeruginosa* isolates by Epsilometer test (E test)**

Determination of MIC *P. aeruginosa* isolates by Imipenem (IP)-E test and Meropenem (MP)-E test (bioMérieux SA, Marcy l'Etoile, France). Results were interpreted using CLSI (2016) breakpoints. The breakpoints for imipenem and meropenem were as follows: susceptible (S) ≤4 μg/ml and resistant (R) ≥16 μg/ml.

**MBL screening and confirmation by phenotypic methods**

Combination disk diffusion test (CDDT) was used for phenotypic detection of MBLs producing *P. aeruginosa* strains. In brief a 0.5 M EDTA solution was prepared and then was added to 10 μg imipenem and meropenem disks to obtain a concentration of 750 μg. The IPM and IPM-EDTA disks were placed on the plate which were inoculated with *P. aeruginosa*. The inhibition zones of these disks with and without EDTA solution were compared after 16-18 hrs of incubation in air at 35°C. An increase of ≥7 in the zone diameter for IPM in the presence of EDTA was considered as positive result.

Double-disk synergy test (DDST), in brief a 10 μl of 0.5 M (750 μg) EDTA solution was added to filter paper blank disc, was placed on the surface of the agar plate. IPM disc (10 μg) or MEM disc (10 μg) was placed 13 mm center to center from the EDTA disc. The plates were incubated for 16-18 hrs at 35°C. Enhancement of the inhibition zone in the area between the imipenem (or meropenem) disc and the EDTA disk in comparison with the inhibition zone on the far side of the drug was interpreted as positive for MβL production.
RESULTS AND DISCUSSION

Results

Isolation and Identification of pathogens were done on specimens according to standard procedures. 412 isolates from different clinical samples were collected. Out of 412 isolates, Enterobacteriaceae sp. were the most common isolates detected, they were 226 (54.85%). The incidence of other microorganisms was P. aeruginosa 74 (17.96%), Staphylococci sp. 98 (23.79%) and Candida sp. 14 (3.4%). Microbial isolates are shown in table 1.

Distribution of P. aeruginosa isolates among different wards/ICUs. P. aeruginosa isolates were mostly isolated from Urology department representing 32.4% (24/74) from total P. aeruginosa isolates, followed by General ICU representing 24.3% (18/74), Chest ICU and neurology ICU representing 10.8% (8/74), internal medicine ICU 9.5% (7/74), pediatric ICU 6.8% (5/74), and then postoperative ICU representing 5.4% (4/74) are shown in figure 1.

Antimicrobial susceptibility. The highest sensitivity was to imipenem 38 isolates (51.3%). The antibiotic sensitivity then decrease in descending manner to be meropenem (48.6%) > levofloxacin (28.4%) > ciprofloxacin and ceftazidime (21.6%) while the highest resistance rates were to carbenicillin 70 isolates (94.6%) then gentamicin (70.3%). The rate of resistance to antibiotics is shown in the table (2). Out of 74 P. aeruginosa isolates, 51 (69%) strains were MDR and 23 (32%) strains were non-MDR strains.

Determination for P. aeruginosa isolates. All P. aeruginosa isolates (74 isolates) were tested for accurate determination of their MIC using the Imipenem (IP)-E test and Meropenem (MP)-E test strips. Results were interpreted using the breakpoints of CLSI (2016) as shown in figure 2.
**Table 2:** Antimicrobial susceptibility pattern of 74 *P. aeruginosa* urine isolates.

| Antimicrobial drug | No. of resistant isolates (%) | No. of intermediate isolates (%) | No. of sensitive isolates (%) |
|-------------------|-------------------------------|----------------------------------|-----------------------------|
| Imipenem          | 27 (36.5%)                    | 9 (12.2%)                        | 38 (51.3%)                  |
| Meropenem         | 29 (39.2%)                    | 9 (12.2%)                        | 36 (48.6%)                  |
| Ceftazidime       | 49 (66.2%)                    | 9 (12.2%)                        | 16 (21.6%)                  |
| Amikacin          | 43 (58.1%)                    | 19 (25.7%)                       | 12 (16.2%)                  |
| Gentamicin        | 52 (70.3%)                    | 9 (12.2%)                        | 13 (17.5%)                  |
| Ciprofloxacin     | 51 (68.9%)                    | 7 (9.5%)                         | 16 (21.6%)                  |
| Levofloxacin      | 46 (62.1%)                    | 7 (9.5%)                         | 21 (28.4%)                  |
| Carbenicillin     | 70 (94.6%)                    | 1 (1.4%)                         | 3 (4%)                      |

**Fig. 2:** Results of MIC of Imipenem and Meropenem using (IP)-E test and (MP)-E test strips in 74 *P. aeruginosa* isolates.

**Detection of MBL by CD.** Out of the 74 *P. aeruginosa* isolates, 26 (35.1%) and 25 isolates (33.8%) showed an increase in the zone of inhibition of about 7 mm or more around IPM-EDTA and MEM-EDTA disks compared to IPM and MEM disk alone (positive for MβLs production), respectively shown in the figure 3 and table 3.

**Detection of MBL by DDST.** Out of the total 74 *P. aeruginosa* isolates, 23 (31.1%) and 21 isolates (28.4%) showed positive results for MβLs production using IPM and MEM, respectively, are shown in the figure 4 and table 4, but all IP and MP E-test susceptible *P. aeruginosa* isolates showed negative results of DDST.

**Discussion**

This study included patients suffering from nosocomial UTIs over a period of 17 months from November 2015 to April 2017. The aerobic pathogens causing UTI were identified. The antibiotic resistance pattern, for *P. aeruginosa* isolates was performed, the frequency of multidrug resistance among nosocomial *P. aeruginosa* infections, and carbapenems antibiotic sensitivity pattern of *P. aeruginosa* isolates were determined. Phenotypic detection of Metallo-β-lactamase production.
Table 3: Results of CD test of all 74 \textit{P. aeruginosa} isolates using IPM (10 \(\mu\)g) and MEM (10 \(\mu\)g) for M\(\beta\)L detection.

| Sample | CDT using IPM | | CDT using MPM | |
|---|---|---|---|---|
| | Positive | Negative | Positive | Negative |
| | No. (%) | No. (%) | No. (%) | No. (%) |
| Total No of \textit{P. aeruginosa} isolates (\(n=74\)) | 26 (35.1%) | 48 (64.9%) | 25 (33.8%) | 49 (66.2%) |

Fig. 3: Detection of M\(\beta\)L in carbapenem resistant \textit{P. aeruginosa} isolate by CD test (+Ve).

Table 4: \textit{P. aeruginosa} isolates using IPM (10 \(\mu\)g) and MEM (10 \(\mu\)g) for M\(\beta\)L detection.

| Sample | DDST using IPM | | DDST using MPM | |
|---|---|---|---|---|
| | Positive | Negative | Positive | Negative |
| | No. (%) | No. (%) | No. (%) | No. (%) |
| Total No of \textit{P. aeruginosa} isolates (\(n=74\)) | 23 (31.1%) | 51 (68.1%) | 21 (28.4%) | 53 (71.6%) |

Fig. 4: Detection of M\(\beta\)L in carbapenem resistant \textit{P. aeruginosa} isolate by DDST (+Ve).
During the study period, rate of isolation of nosocomial *P. aeruginosa* urine isolates was 17.96% of isolated uropathogens. This finding agreed to some extent with that reported by Gad et al., who identified *P. aeruginosa* isolates in 18.2% of the clinical samples and Wassaf et al., who identified *P. aeruginosa* isolates in 20.7% of different clinical samples. This rate were much higher than that reported by Aminizadeh and Kashi, where the rate of incidence of *P. aeruginosa* in UTI was 13.2%. In Malaysia, also Abbas et al., who identified *P. aeruginosa* isolates in (12.5%) of the clinical samples and Mohammedi et al., who identified *P. aeruginosa* isolates in (12.35%) of different clinical samples. However, these results were less than those found by Mansour et al., who reported that the rate of isolation of *Ps. aeruginosa* from patient samples in Egypt and Saudi Arabia, was 32.8% and 30.0% respectively.

The leading uropathogens in this study were *Enterobacteriaceae sp.* (54.85%). This was comparable to that reported by in Sudan reported by Shareef and Yagoub (68.01%) and to Milan and Ivan in Serbia (64%). There were much higher rates reported in Nepal and Pakistan by Chandrashekar et al. and Khan et al., On the other hand rates ranging from (25) to (37.4%) were reported in Japan and Turkey by Shigemura et al. and Savas et al.

In this study candida sp. forms (3.4%) of isolated pathogens. This rate was more or less similar to (3.7%) found in India by Hasan et al. lower than reported in Kuwait (16.5%) by Al Benwan et al. In Saudi Arabia, the frequency of nosocomial uro-pathogens isolates was studied by Alzohairy and Khadri, where they showed that *E. coli* was the predominant pathogen and Klebsiella spp. were the second common organism in hospital-acquired infection followed by *P. aeruginosa* strains.

In our study, the highest number of *P. aeruginosa* strains were recovered from the Urology department followed by General ICU then chest ICU and neurology ICU with percentages of 32.4% (24/74), 24.3% (18/74), 10.8% (8/74) and 10.8% (8/74), respectively (Fig. 1). These findings disagree to some extent with those of Juvanbakht et al. who reported that Postoperative ICU were the most frequent category of infection (46.5%) in Imam Reza hospital, followed by Urology department (22.7%), and General ICU (9%). These differences may be due to difference in the number of patients, place of study and genetic susceptibility.

The present study revealed that the resistance rates of *P. aeruginosa* were ranging from very high (94.6%) to carbenicillin to moderate to ceftazidime (66.2%) and high incidence of resistance can explain by our routine use of the drug (Table 2). These high values of resistance which were observed were comparable to those of the reports from Gujarat, with a resistance value of (75%)²⁸. Also, our results were consistent with data of Fazlul et al., who stated that nosocomial *P. aeruginosa* urine isolates were highly resistant to ceftazidime (61.9%).

In our study, the rate of resistance of *P. aeruginosa* urine isolates to imipenem was (36.5%) and to meropenem was (39.2%) in the same table. Our results were identical with those reported by Ashour and El-Sharif in Egypt who concluded that Acinetobacter and Pseudomonas species exhibited the highest resistance levels to imipenem (37.03%) among other Gram-negative organisms.

Our results were higher than those reported by Wang et al. documented low rate of imipenem and meropenem-resistance among *P. aeruginosa*, it was (13%) and (16%) respectively. Queenan et al. stated that rate of imipenem and meropenem resistance among *P. aeruginosa* isolated from patients with UTIs was (18%) and (22%), respectively. Resistance rates to carbenapem may vary and depends on local antibiotic policies, origin of the strains, and geographic location.

Our study showed marked increase in imipenem resistance (39.2%) which may be attributed to increased use of imipenem in the hospital. This rate of carbapenem resistance reflects a threat limiting the treatment options in our hospitals. This can be explained in part by the increase in consumption of antimicrobial agents in the last decade leading to a selective pressure of antibiotics on *P. aeruginosa* and consequently the bacteria modify the resistant mechanisms. A similar high rate of resistance
has been reported in many developing countries worldwide.\textsuperscript{34}

The resistance rate of \textit{P. aeruginosa} to gentamicin was (70.3%) and amikacin was (58.1%). In agreement with our result, Fazlul \textit{et al.}\textsuperscript{29}, observed that the resistance of nosocomial \textit{P. aeruginosa} urine isolates to gentamicin and amikacin was (75%) and (48%) respectively. Ramirez and Tolmasky\textsuperscript{35} reported much high rate of resistance to gentamicin (81%). Sibi \textit{et al.}\textsuperscript{36} found that resistance of \textit{P. aeruginosa} to gentamicin and amikacin was (79%) and (51%), respectively. Zhao \textit{et al.}\textsuperscript{37} found that the resistance rate of \textit{P. aeruginosa} to gentamicin and amikacin was (77%) and (61%), respectively.

Fluoroquinolones are most commonly used in urinary tract infections. But resistance to fluoroquinolones is increasing. The resistance rate to ciprofloxacin was (68.9%) and levofloxacin was (62.2%). These results were similar to those reported by Gad \textit{et al.}\textsuperscript{12}, who found that most of the \textit{P. aeruginosa} isolates were resistant to both levofloxacin (64%), and ciprofloxacin (62%). Abbas \textit{et al.}\textsuperscript{15} also found that most of the \textit{P. aeruginosa} isolates were resistant to levofloxacin (69.4%), and ciprofloxacin (67.1%). These results disagree with the study of Kobayashi \textit{et al.}\textsuperscript{38} who found that (22.4%) of the \textit{P. aeruginosa} isolates were resistant to ciprofloxacin. These rates were lower than that reported by Manjunath \textit{et al.}\textsuperscript{39} in India where the rate of ciprofloxacin resistance was (85%).

In our study, the prevalence of MDR strains among \textit{P. aeruginosa} urine isolates was 51 (69%). Our result was coincides with studies that were done by Mohanasoundaram\textsuperscript{40} who found that, the percentage of the MDR in the \textit{P. aeruginosa} strains had increased from (64%) in 2008 to (71%) in 2010; Alzohairy and Khadri\textsuperscript{26} found that, \textit{P. aeruginosa} (58.3%) was the most common MDR uro-pathogens followed by \textit{E. faecalis} (55.5%) and \textit{E.coli} (53.6%). Our results was higher than Kirikae \textit{et al.}\textsuperscript{41} who reported that the percentage of MDR- \textit{P. aeruginosa} isolates in the urinary tract was significantly greater in both medical facilities and clinical laboratories, where the percentage of MDR strains was (43.8%) and (41.6%), respectively. However, the result was lower than (76%) reported by El-Shouny \textit{et al.}\textsuperscript{32}.

In this study, phenotypic detection of carbapenemase producing \textit{P. aeruginosa} isolates was done by determination of MICs of carbapenems using E-test. IP & MP E-test identified 27 carbapenemase-producing \textit{P. aeruginosa} isolates. IP E-test results showed that 36.5% (27/74) of \textit{P. aeruginosa} isolates were imipenem resistant (MIC above 16 µg/ml), while 6.8% (5/74) of the isolates showed imipenem intermediate susceptibility (MIC 8 µg/ml) and 56.7% (42/74) of the isolates were imipenem sensitive (MIC below 4 µg/ml) (Fig. 2). These results were similar to those reported by Arora \textit{et al.}\textsuperscript{43} who found that rate of imipenem- resistant among \textit{P. aeruginosa} urine isolates was (37%). In the Middle East the occurrence of imipenem resistant \textit{P. aeruginosa} is alarmingly recognized. In Saudi Arabia, the resistance rate of \textit{P. aeruginosa} to imipenem was increased to (38.57%) in 2011.\textsuperscript{44}

MP E-test results showed that 39.2% (29/74) of \textit{P. aeruginosa} isolates were meropenem resistant (MIC above 16 µg/ml), while 2.7% (2/74) of the isolates showed meropenem intermediate susceptibility (MIC 8 µg/ml) and 58.1% (43/74) of the isolates were meropenem sensitive (MIC below 4 µg/ml). In agreement with our results, a study in Egypt reported a resistance rate of (37.7%) to meropenem among \textit{P. aeruginosa} isolated from hospitalized cancer patients.\textsuperscript{35} This is explained by the differences in the pattern of antibiotic prescription and usage between the two studies.

In our study, CDT and DDST were done as phenotypic methods for detection of MBL-producing \textit{P. aeruginosa} isolates including both carbapenem susceptible and non-susceptible strains. By CDT, 35.1% (26/74) and 33.8% (25/74) of \textit{P. aeruginosa} isolates were MBL producers phenotypically by IPM/EDTA and MEM/EDTA combined disks, respectively (Table 3). These findings are similar to high extent to the prevalence of MBL producers in Egyptian study which was (32.3%) by Mansour \textit{et al.}\textsuperscript{17}, from UK (38.3%) by Ellington \textit{et al.}\textsuperscript{46}.

Regarding the DDST, 31.1% (23/74) and 28.4% (21/74) of \textit{P. aeruginosa} isolates were

167
MβL producers phenotypically by IPM and MEM, respectively (Table 4). These results are in accordance with those of other studies in Egypt by Mansour et al. 17 who reported that the prevalence of MβL producers in Egyptian study was (32.3%). In 2012, Polotto et al. 47 surveyed 56 P. aeruginosa isolates by disk diffusion method and showed that 54/56 (96.4%) of isolates were resistant to imipenem. They also showed that 17 /56 (30.3%) of imipenem-resistant strains were positive for production of MBL.

Conclusion

This study shows that there is increasing prevalence of β-lactamase producing P. aeruginosa in nosocomial infections in AL-Azher University Hospital This is a major cause of concern as this implies that more and more instances of multidrug resistance are emerging. This leads to an overall negative impact on the health concerns and amounts to increasing difficulty in combating disease. It is recommended that awareness about antibiotic use and abuse be made a priority and measures of curbing unchecked use of prescription antibiotics be put into place. Establishment of infection control programs will help to lower the incidence of resistance in P. aeruginosa.

REFERENCES

1- A. Y. Peleg and D. C. Hooper, "Hospital-acquired infections due to gram-negative bacteria", New Engl. J. Med., 362 (19), 1804-1813 (2010).
2- J. A. Adachi, C. Perego, L. Graviss, T. Dvorak, R. Hachem, R.F. Chemaly, et al., "The role of interventional molecular epidemiology in controlling clonal clusters of multidrug resistant Pseudomonas aeruginosa in critically ill cancer patients", Am. J. Infect. Control., 37 (6), 442-446 (2009).
3- S. Sako, R. Kariyama, R. Mitsuhata, M. Yamamoto, K. Wada, A. Ishii, et al., "Molecular epidemiology and clinical implications of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from urine", Acta. Med. Okayama, 68, 89-99 (2014).
4- S. Bratu, J. Quale, S. Cebular, R. Heddurshetti and D. Land-man, "Multidrug resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in-vitro activity of polymyxin B", Eur. J. Clin. Microbiol. Infect. Dis., 24, 196-201 (2005).
5- A. P. Magiorakos, A. Srinivasan, R. B. Carey, Y. Carmeli, M. E. Falagas, et al., "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance", Clin. Microbiol. Infect., 18, 268-281 (2012).
6- D. M. Livermore, "Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare?", Clin. Infect. Dis., 34, 634-640 (2002).
7- M. R. Franco, H. H. Caiaffa-Filho, M. N. Burattini and F. Rossi, "Metallobeta-lactamases among imipenem-resistant Pseudomonas aeruginosa in a Brazilian University Hospital", Clinics (Sao Paulo), 65 (9), 825-829 (2010).
8- R. E. Mendes, M. Castanheira, M. A. Toleman, H. S. Sader, R. N. Jones, and T. R. Walsh, "Characterization of an integron carrying blalMP-1 and a new aminoglycoside resistance gene (aac(6’)-31), and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital", Antimicrob. Agents Chemother., 51, 2611-2614 (2007).
9- Clinical and Laboratory Standards Institute (CLSI). "Performance Standards for Antimicrobials Susceptibility Testing", Twenty First informational Supplement, Wayne, PA 2011, CLSI document, M100-S21.
10- Clinical and Laboratory Standards Institute. "Performance Standards for Antimicrobial Susceptibility Testing", 26th Edn., Wayne, PA 2016, CLSI document, M100-S21.
11- D. Yong, K. Lee, J. H. Yum, J. H. Shin, G. M. Rossolini and Y. Chong, "Imipenem-EDTA disk method for differentiation of MsL producing clinical
isolates of *Pseudomonas* spp. and *Acinetobacter* spp.", *J. Clin. Microbiol.*, 40, 3798-3801 (2002).

12- G. F. Gad, R. A. El-Domany, S. Zaki and H. M. Ashour, "Characterization of *Pseudomonas aeruginosa* isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms", *Journal of Antimicrobial Chemotherapy*, 60, 1010-1017 (2007).

13- M. Wassef, H. El Mahallawy, M. M. Zafer, G. Doaa and R. Abdel hamid, "Lab Based Surveillance of Multidrug Resistant *Pseudomonas aeruginosa* in Cairo University Hospitals, Egypt", *Journal of Microbiology & Experimentation*, 2 (2), 1-5 (2015).

14- Z. Aminizadeh and M. S. Kashi, "Prevalence of MDR and PDR among multiple Gram-negative spp.; experience in one teaching hospital, Tehran, Iran", *International Research Journal of Microbiology*, 2 (3), 090-095 (2011).

15- S. H. Abbas, M. Naeem, M. Adil, S. M. Naz, A. Khan and M. U. Khan, "Sensitivity patterns of *Pseudomonas aeruginosa* isolates obtained from clinical specimens in Peshawar", *Journal of Ayub Medical College Abbottabad*, 27, 329-332 (2015).

16- M. Mohammadi, E. Ghasemi, H. Mokhayeri, Y. Pournia and H. Boroun, "Antimicrobial resistance patterns of *E. coli* detected from hospitalized urine culture samples", *Asian J. Biol. Sci.*, 3, 195-201 (2010).

17- S. Mansour, O. Eldaly, A. Jiman Fatani, M. Mohamed and E. Ibrahim, "Epidemiological characterization of *Ps. aeruginosa* isolates of intensive care units in Egypt and Saudi Arabia", *East Mediter Health J.*, 19, 71-80 (2013).

18- S. A. Shareef and S. O. Yagoub, "Incidence and Isolation of Bacteria Associated With Nosocomial Urinary Tract Infection(UTI) in Sudanese Women", *Research Journal of Microbiology*, 5 (12), 1289-1294 (2010).

19- P. B. Milan and M. I. Ivan, "Catheter-associated and nosocomial urinary tract infections: antibiotic resistance and influence on commonly used antimicrobial therapy", *Int. Urol. Nephro.*, 41, 461-464 (2009).

20- R. N. Chandrashekhar, H. S. Joshi, M. Gurung, N. Shrestha and P. G. Shivananda, "Frequency and susceptibility profile of pathogens causing urinary tract infections at a tertiary care hospital in western Nepal", *Singapore Med. J.*, 47 (4), 281-285 (2006).

21- B. A. Khan, S. Saeed, A. Akram, F. B. Khan and A. Nasim, "Nosocomial Uropathogens And Their Antibiotic Sensitivity Patterns In A Tertiary Referral Teaching Hospital In Rawalpindi, Pakistan", *J. Ayub. Med. Coll. Abbottabad*, 22 (1), 11-12 (2010).

22- K. Shigemura, K. Tanaka, H. Okada, Y. Nakano, S. Kinoshita, *et al.*, "Pathogen occurrence and antimicrobial susceptibility of urinary tract infection cases during a 20-year period (1983-2002) at a single institution in Japan", *Jap. J. Infect. Dis.*, 58, 303-308 (2005).

23- L. Savaș, N. Duran, N. Savaș, Y. Knlen and S. Ocak, "The prevalence and resistance patterns of *Pseudomonas aeruginosa* in intensive care units in a university hospital", *Turk. J. Med. Sci.*, 35, 317-322 (2006).

24- A. S. Hasan, D. Nair, J. Kaur, G. Baweja, M. Deb and P. Aggarwal, "Resistance Patterns Of Urinary Isolates In A Tertiary Indian Hospital", *J. Ayub. Med. Coll. Abbottabad*, 19 (1), 39-41 (2007).

25- K. Al Benwan, N. Al Sweih and V. O. Rotimi, "Etiology and antibiotic susceptibility patterns of community- and hospital-acquired urinary tract infections in a General Hospital in Kuwait", *Med. Princ. Pract.*, 19, 440-446 (2010).

26- M. Alzohairy and H. Khadri, "Frequency and antibiotic susceptibility pattern of uropathogens isolated from community and hospital-acquired infections in Saudi Arabia - A prospective case study", *British Journal of Medicine & Medical Research*, 1 (2), 45-56 (2011).

27- A. Javanbakht, E. Askari, L. Danesh, N. Moghadas, I. Mostafavi and M.
Naderinasab, "The incidence of cross infections in Imam Reza hospital, Mashhad, Iran", *Iranian Journal of Microbiology*, 4, 177-179 (2012).

28- W. H. Zhao and Z. Q. Hu ZQ. "β-lactamses identified in clinical isolates of *Pseudomonas aeruginosa*", *Crit. Rev. Microbiol.*, 36, 245-258 (2010).

29- M. K. Fazlul, M. Z. Zaini, M. A. Rashid and M. H. Nazmul, "Antibiotic susceptibility profiles of clinical isolates of *Pseudomonas aeruginosa* from Selayang Hospital, Malaysia", *Biomedical Research*, 22 (3), 263-266 (2011).

30- H. M. Ashour and A. El-Sharif "Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients", *J. Transl. Med.*, 7 (1), 14 (2009).

31- J. Wang, J. Y. Zhou, T. T. Qu, P. Shen, *et al.*, "Molecular epidemiology and mechanisms of carbapenem resistance in *Pseudomonas aeruginosa* isolates from Chinese Hospitals", *Int. J. Antimicrob. Agents*, 35, 486-491 (2010).

32- A.M. Queenan, W. Shang, K. Bush and R. K. Flamm, "Differential selection of single-step AmpC or efflux mutants of *Pseudomonas aeruginosa* by using cefepime, ceftazidime, or ceftobiprole", *Antimicrob. Agents Chemother.*, 54, 4092-4097 (2010).

33- A. Singh, V. G. Richard, S. Shabbir, L.F. Steven and J. Z. Marcus, "Application of Molecular Techniques to the Study of Hospital Infection", *Clin. Microbiol Rev.*, 19 (3), 512-530 (2006).

34- R. C. Picao, L. Poirel, A. C. Gales and P. Nordmann, "Diversity of β-lactamas produced by ceftazidime-resistant *Pseudomonas aeruginosa* isolates causing blood-stream infections in Brazil", *Antimicrob. Agents Chemother.*, 53, 3908-3913 (2009).

35- M. S. Ramirez and M. E. Tolmasky, "Aminoglycoside modifying enzymes", *Drug Resist.*, 13, 151-171 (2010).

36- G. Sibi, A. P. Devi, K. Fouzia and B. R. Patil, "Prevalence, microbiologic profile of UTI and its treatment with trimethoprim in diabetic patients", *Res. J. Microbiol.*, 6 (6), 543-551 (2011).

37- W. H. Zhao, G. Chen, R. Ito and Z. Q. Hu, "Relevance of resistance levels to carbapenems and integron-borne blaIMP-1, blaIMP-7, blaIMP-10 and blaVIM-2 in clinical isolates of *Pseudomonas aeruginosa*", *J. Med. Microbiol.*, 58, 1080-1085 (2009).

38- H. Kobayashi, M. Isozaki, T. Fukuda, Y. Anzai and F. Kato, "Surveillance of fluoroquinolone-resistant clinical isolates of *Pseudomonas aeruginosa*", *Op. J. Med. Microbiol.*, 3, 144-150 (2013).

39- G. N. Manjunath, R. Prakash, V Annam and K. Shetty, "Changing trends in the spectrum of antimicrobial drug resistance pattern of uropathogens isolated from hospitals and community patients with urinary tract infections in Tumkur and Bangalore", *Int. J. Biol. Med. Res.*, 2 (2), 504-507 (2011).

40- K. M. Mohanasoundaram, "The antimicrobial resistance pattern in the clinical isolates of *Pseudomonas aeruginosa* in a Tertiary Care Hospital, 2008-2010 (A 3 Year Study)", *Journal of Clinical and Diagnostic Research*, 5 (3), 491-494 (2011).

41- T. Kirikae, Y. Mizuguchi and Y. Arakawa, "Investigation of isolation rates of *Pseudomonas aeruginosa* with and without multidrug resistance in medical facilities and clinical laboratories in Japan", *J. Antimicrob. Chemother.*, 61 (3), 612-615 (2008).

42- W. A. El-Shouny, S. S. Ali, J. Sun, S. M. Samy and A. Ali, "Drug resistance profile and molecular characterization of extended spectrum β-lactamase (ESBL)-producing *Pseudomonas aeruginosa* isolated from burn wound infections. Essential oils and their potential for utilization", *Microbial Pathogenesis*, 116, 301-312 (2018).

43- D. Arora, N. Jindal, R. Kumar and A. Romit, "Emerging antibiotic resistance in *Pseudomonas aeruginosa* challenge", *Int. J. Pharm. Pharm. Sci.*, 3 (2), 82-84 (2011).
44- A. A. Mohamed, A. M. Shibl, S. A. Zaki and A. F. Tawfik, "Antimicrobial resistance pattern and prevalence of metallo-β-lactamases in Pseudomonas aeruginosa from Saudi Arabia", *African Journal of Microbiology Research*, 5 (30), 5528-5533 (2011).

45- J. W. Decousser, P. Pina, F. Picot, C. Delalande, *et al.*, "Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey", *J. Antimicrob. Chemother.*, 51 (5), 1213-1222 (2003).

46- M. J. Ellington, J. Kistler, D. M. Livermore and N. Woodford, "Multiplex PCR for rapid detection of genes encoding acquired metallo-β-lactamases", *Antimicrob. Chemother.*, 59 (2), 321-322 (2007).

47- M. Polotto, T. Casella, M. G. Oliveira, F. G. Rubio, M. L. Nogueira, *et al.*, "Detection of Pseudomonas aeruginosa harboring blaCTX-M-2, blaGES-1 and blaGES 5, blaIMP-1 and blaSPM-1 causing infections in Brazilian tertiary-care hospital", *BMC Infect. Dis.*, 12, 176 (2012).
تحديد وتوصيف الميثالوبيتالاكتاميز المنتج من عزلات متكاثرات السيدوموناس أيريجينوزا السريرية في المستشفى الأزهر الجامعي

رواب صحاب مصليهم موسى يرجى - مهدى موسى القاضي - أسماء عبد الناصر حسين - عمرو السيد أحمد - أحمد سامي الجملي

صلاح محمد بن عبد الرحمن - جامعي بي بي سي، بني سوف، بني سوف، مصر

وكأس امار الدواجن، كلية الطب البيطري، جامعة بني 사وف، بني سوف، مصر

قسم الأمراض المشتركة، كلية الطب البيطري، وعميد معهد بحوث دراسات البيولوجيا الجزيئية، جامعة أسيوط، مصر

قسم البوتنيكولوجيا وعلوم الحياة، كلية الدراسات والعلوم المقدمة، جامعة بني سوف، بني سوف، مصر

قسم الميكروبولوجيا والمناعة، كلية الصيدلة، جامعة بني سوف، بني سوف، مصر

هذة الدراسة طُلبت من انتشار بكتيريا السودوموناس أيريجينوزا في مرضى العدوى المكتسبة في وحدات العناية المركزية المختلفة وقسوة المسالك البولية في مستشفى الأزهر الجامعي بأسيوط، تم جزء (71٪) عزل من ميكروب السودوموناس أيريجينوزا بنسبة 16٪ من الإجمالي الكلي للميكروب والجزء (29٪) عزل من السودوموناس أيريجينوزا تم العثور عليها في قسم المسالك البولية (44٪) ووحدة العناية المركزية عامة (20٪)، تليها كل من وحدة العناية المركزية الصدر الباطني ووحدة العناية المركزية العصبية بنسبة (10٪)، ثم وحدة العناية المركزية الباطني بنسبة (9٪)، ووحدة العناية المركزية الباطني إطفال بنسبة (5٪) وفترة وحدة العناية المركزية بعد العمليات (5٪).

تم دراسة حساسية السودوموناس أيريجينوزا المعزولة للمضادات الحيوية المختلفة بواسطة طريقة الانتشار القرصي، أظهرت النتائج أن (64٪) كانت مقاومة للكلوريسيلين (70٪) مقاومة للجينتناميسين (51٪) مقاومة لكل من سيرفلوكساسين (49٪) مقاومة لسيفرنتازيد (46٪) و (21٪) مقاومة للغريفوكساسين (43٪) مقاومة لتيتيوكساسين (41٪) مقاومة لميدروديثين (21٪) مقاومة لليثيوكلساسين (29٪) مقاومة لميديبيردين (27٪) مقاومة للإيميديزول و 29٪ مقاومة للإيميدوزول و 29٪ من المرضى كانت مقاومة للايباميبين، مما وضعت الدراسة أن نسبة الحالات المعتادة لأدوية معددة كثير من مضادات ميكروبية كانت تتمثل 29٪، ونسبة السلالات غير متحدة المقاومة للمضادات الحيوية كانت تتمثل 31٪.

تم تحديد دندي تركيز مثبط MIC للمضادات الحيوية للايباميبين والميديبيردين بواسطة اختبار MP-E و MP-E وIP-E. أظهرت نتائج اختبار IP-E أن 39، وناتج اختبار MP-E لوحظ أن 39، وناتج اختبار MP-E. وناتج اختبار MP-E. وقد تم أيضا الكشف الظاهر للاستيروماكريس الميثالوبينيا-لاكازين في جميع مخلوطات السودوموناس أيريجينوزا بعد طرق ظاهرة مختلفة منها: اختبار الفرص المشترك واختبار الفرص مزدوج الانتزاز باستخدام فرس المضادات الحيوية إيميدوزول وميديبيردن ذات التركيز 10 ميكروجرام.